Application of MIDD in Clinical Research of Antitumor Drugs / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 487-492, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-939736
ABSTRACT
The antitumor drug has become one of the focused areas in new drug research and development. Their clinical research generally consumes a long period of time, with high cost and high risk. Model-informed drug development (MIDD) integrates and quantitatively analyzes physiological, pharmacological, and disease progression information through modeling and simulation, which can reduce the cost of drug development and improve the efficiency of clinical research. In this essay, Osimertinib and Pembrolizumab are given as examples to illustrate the specific application of MIDD in different phases of clinical research, aiming to provide references for the application of MIDD to guide the clinical research of antitumor drugs.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Drug Development
/
Lung Neoplasms
/
Antineoplastic Agents
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS